NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

University of Toronto

Status: Terminated

Conditions: In-vitro Fertilization; Infertility

Treatments: Drug: NuvaRing; Drug: marvelon

Study type: Interventional

Funder types: Other

Identifiers

NCT01298128

CFRH- 001

Details and patient eligibility

About

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Enrollment: 70 patients

Sex: Female

Ages: 18 to 38 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients less than 38 years of age.
• Healthy women starting their first IVF/ICSI cycle.
• No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1
• Consent to randomization.

Exclusion criteria

• Any contraindication to COC use.
• Hypersensitivity to Nuva ring or any of its components.
• Language barrier to consent.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

70 participants in 2 patient groups

NuvaRing

Experimental group

Description:

NuvaRing for IVF pre-treatment

Treatment:

Drug: NuvaRing

Combined oral contraceptive pill

Active Comparator group

Description:

OCP for IVF pre-treatment

Treatment:

Drug: marvelon